Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase

Detalhes bibliográficos
Autor(a) principal: Madureira, Brunela Pitanga Ramos
Data de Publicação: 2015
Tipo de documento: Tese
Idioma: por
Título da fonte: Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
Texto Completo: http://repositorio.ufes.br/handle/10/1341
Resumo: The present study investigated subclinical Mycobacterium leprae infection in human immunodeficiency virus (HIV) infected or uninfected individuals by measuring antibodies against M. leprae phenolic glycolipid I (PGL-I). It also sought to establish whether the serology results correlated with the HIV-infected participants’ state of immunosuppression. This was a cross-sectional study that analysed the anti-PGL-I immunoglobulin M antibody levels in 350 HIV-infected and 350 non-HIV-infected individuals residing in an area endemic for the two investigated conditions. The possible correlation between the state of immunosuppression of the HIV-infected participants (CD4+ cell count, viral load and the use or not of antiretroviral therapy) and anti-PGL-I seropositivity was assessed. Approximately 6% (21/350) of the HIVinfected and 29.1% (102/350) of the non-HIV-infected participants were anti-PGL-I antibody seropositive. The number of anti-PGL-I antibody seropositive individuals was approximately five-fold higher in the non-HIV-infected group, compared with the HIV-infected group. There was no significant correlation between the state of immunosuppression of the HIV-infected participants and the anti-PGL-I serology results. The HIV-infected individuals exhibited less anti-PGL-I antibody production relative to the control group, which may indicate a lower rate of subclinical M. leprae infection and/or lower specific production of this antibody. B cell dysregulation might cause the low anti-PGL-I antibody production in HIV-infected individuals. The patients’ state of immunosuppression did not correlate with the anti-PGL-I serology results.
id UFES_f578dff158ccb4129da9e45eb67c3d87
oai_identifier_str oai:repositorio.ufes.br:10/1341
network_acronym_str UFES
network_name_str Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
repository_id_str 2108
spelling Deps, Patrícia DuarteMadureira, Brunela Pitanga RamosFalqueto, AloisioPalaci, MoisesAntunes, João Marcelo Azevedo de PaulaHadad, David Jamil2015-04-09T19:24:46Z2016-06-24T06:00:07Z2015-02-262015-02-26The present study investigated subclinical Mycobacterium leprae infection in human immunodeficiency virus (HIV) infected or uninfected individuals by measuring antibodies against M. leprae phenolic glycolipid I (PGL-I). It also sought to establish whether the serology results correlated with the HIV-infected participants’ state of immunosuppression. This was a cross-sectional study that analysed the anti-PGL-I immunoglobulin M antibody levels in 350 HIV-infected and 350 non-HIV-infected individuals residing in an area endemic for the two investigated conditions. The possible correlation between the state of immunosuppression of the HIV-infected participants (CD4+ cell count, viral load and the use or not of antiretroviral therapy) and anti-PGL-I seropositivity was assessed. Approximately 6% (21/350) of the HIVinfected and 29.1% (102/350) of the non-HIV-infected participants were anti-PGL-I antibody seropositive. The number of anti-PGL-I antibody seropositive individuals was approximately five-fold higher in the non-HIV-infected group, compared with the HIV-infected group. There was no significant correlation between the state of immunosuppression of the HIV-infected participants and the anti-PGL-I serology results. The HIV-infected individuals exhibited less anti-PGL-I antibody production relative to the control group, which may indicate a lower rate of subclinical M. leprae infection and/or lower specific production of this antibody. B cell dysregulation might cause the low anti-PGL-I antibody production in HIV-infected individuals. The patients’ state of immunosuppression did not correlate with the anti-PGL-I serology results.Esse estudo investiga a infecção subclínica de Mycobacterium leprae em pacientes infectados e não infectados pelo HIV, através da dosagem de anticorpos anti-PGL-I, e avalia se existe uma possível correlação dos resultados sorológicos encontrados com o estado de imunossupressão dos pacientes infectados pelo HIV. Foi realizado um estudo transversal analítico em 350 pacientes infectados pelo HIV e em 350 pacientes não infectados pelo HIV para detecção de anticorpos IgM anti-PGL-I em região endêmica para hanseníase. Avaliou-se uma possível correlação do estado de imunossupressão dos pacientes infectados pelo HIV (contagem de linfócitos CD4+, carga viral e uso ou não de terapia antirretroviral) com a soropositividade para PGLI. Dentre os pacientes infectados pelo HIV, 6% (21/350) apresentaram sorologia positiva para PGL-I e dos indivíduos não infectados pelo HIV, 29,1% (102/350) tinham PGL-I positivo. O grupo controle apresentou cerca de cinco vezes mais indivíduos com anticorpos anti-PGL-I do que o grupo infectado pelo HIV. Não houve diferença estatisticamente significativa na correlação do estado de imunossupressão do paciente com o resultado da sorologia anti-PGL-I. Houve uma menor produção de anticorpos anti-PGL-I em indivíduos infectados pelo HIV, o que pode indicar uma baixa taxa de infecção subclínica por M. leprae, ou uma baixa produtividade específica desses anticorpos, ou ambas as hipóteses. A desregulação de linfócitos B em indivíduos infectados pelo HIV pode ser a causa da baixa produção de anticorpos anti-PGL-I. Não houve correlação do estado de imunossupressão do paciente com o resultado da sorologia anti-PGL-I.Texthttp://repositorio.ufes.br/handle/10/1341porUniversidade Federal do Espírito SantoDoutorado em Doenças InfecciosasPrograma de Pós-Graduação em Doenças InfecciosasUFESBRCentro de Ciências da SaúdeGlicolipídeo fenólico 1CoinfecçãoHanseníaseHIV (vírus)Mycobacterium lepraeDoenças Infecciosas e Parasitárias61Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)instname:Universidade Federal do Espírito Santo (UFES)instacron:UFESORIGINALPesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em area endemica de hanseniase.pdfPesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em area endemica de hanseniase.pdfapplication/pdf595292http://repositorio.ufes.br/bitstreams/7a4243f7-ccae-4749-833b-5edca72e5e39/download91d4c514416e14264549113d0ff5dea1MD51CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://repositorio.ufes.br/bitstreams/fe0dd388-78a9-45af-a0ff-825bde547a4f/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-822376http://repositorio.ufes.br/bitstreams/fe4f15ae-436b-4808-a10a-536154f9c949/downloadb292a83e42bd8ad62533bba1395b83ffMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-823148http://repositorio.ufes.br/bitstreams/ba806369-47cd-4989-a27f-c059385b161b/download9da0b6dfac957114c6a7714714b86306MD54LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repositorio.ufes.br/bitstreams/33f35a13-1c76-48ae-b70b-99dfcb2168f0/download8a4605be74aa9ea9d79846c1fba20a33MD5510/13412024-07-16 17:05:41.186oai:repositorio.ufes.br:10/1341http://repositorio.ufes.brRepositório InstitucionalPUBhttp://repositorio.ufes.br/oai/requestopendoar:21082024-10-15T17:53:59.784919Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES)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
dc.title.none.fl_str_mv Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
title Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
spellingShingle Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
Madureira, Brunela Pitanga Ramos
Glicolipídeo fenólico 1
Doenças Infecciosas e Parasitárias
Coinfecção
Hanseníase
HIV (vírus)
Mycobacterium leprae
61
title_short Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
title_full Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
title_fullStr Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
title_full_unstemmed Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
title_sort Pesquisa de anticorpos anti-PGL-I em pacientes infectados pelo HIV em área endêmica para hanseníase
author Madureira, Brunela Pitanga Ramos
author_facet Madureira, Brunela Pitanga Ramos
author_role author
dc.contributor.advisor1.fl_str_mv Deps, Patrícia Duarte
dc.contributor.author.fl_str_mv Madureira, Brunela Pitanga Ramos
dc.contributor.referee1.fl_str_mv Falqueto, Aloisio
dc.contributor.referee2.fl_str_mv Palaci, Moises
dc.contributor.referee3.fl_str_mv Antunes, João Marcelo Azevedo de Paula
dc.contributor.referee4.fl_str_mv Hadad, David Jamil
contributor_str_mv Deps, Patrícia Duarte
Falqueto, Aloisio
Palaci, Moises
Antunes, João Marcelo Azevedo de Paula
Hadad, David Jamil
dc.subject.por.fl_str_mv Glicolipídeo fenólico 1
topic Glicolipídeo fenólico 1
Doenças Infecciosas e Parasitárias
Coinfecção
Hanseníase
HIV (vírus)
Mycobacterium leprae
61
dc.subject.cnpq.fl_str_mv Doenças Infecciosas e Parasitárias
dc.subject.br-rjbn.none.fl_str_mv Coinfecção
Hanseníase
HIV (vírus)
Mycobacterium leprae
dc.subject.udc.none.fl_str_mv 61
description The present study investigated subclinical Mycobacterium leprae infection in human immunodeficiency virus (HIV) infected or uninfected individuals by measuring antibodies against M. leprae phenolic glycolipid I (PGL-I). It also sought to establish whether the serology results correlated with the HIV-infected participants’ state of immunosuppression. This was a cross-sectional study that analysed the anti-PGL-I immunoglobulin M antibody levels in 350 HIV-infected and 350 non-HIV-infected individuals residing in an area endemic for the two investigated conditions. The possible correlation between the state of immunosuppression of the HIV-infected participants (CD4+ cell count, viral load and the use or not of antiretroviral therapy) and anti-PGL-I seropositivity was assessed. Approximately 6% (21/350) of the HIVinfected and 29.1% (102/350) of the non-HIV-infected participants were anti-PGL-I antibody seropositive. The number of anti-PGL-I antibody seropositive individuals was approximately five-fold higher in the non-HIV-infected group, compared with the HIV-infected group. There was no significant correlation between the state of immunosuppression of the HIV-infected participants and the anti-PGL-I serology results. The HIV-infected individuals exhibited less anti-PGL-I antibody production relative to the control group, which may indicate a lower rate of subclinical M. leprae infection and/or lower specific production of this antibody. B cell dysregulation might cause the low anti-PGL-I antibody production in HIV-infected individuals. The patients’ state of immunosuppression did not correlate with the anti-PGL-I serology results.
publishDate 2015
dc.date.submitted.none.fl_str_mv 2015-02-26
dc.date.accessioned.fl_str_mv 2015-04-09T19:24:46Z
dc.date.issued.fl_str_mv 2015-02-26
dc.date.available.fl_str_mv 2016-06-24T06:00:07Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufes.br/handle/10/1341
url http://repositorio.ufes.br/handle/10/1341
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv Text
dc.publisher.none.fl_str_mv Universidade Federal do Espírito Santo
Doutorado em Doenças Infecciosas
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Doenças Infecciosas
dc.publisher.initials.fl_str_mv UFES
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal do Espírito Santo
Doutorado em Doenças Infecciosas
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
instname:Universidade Federal do Espírito Santo (UFES)
instacron:UFES
instname_str Universidade Federal do Espírito Santo (UFES)
instacron_str UFES
institution UFES
reponame_str Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
collection Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
bitstream.url.fl_str_mv http://repositorio.ufes.br/bitstreams/7a4243f7-ccae-4749-833b-5edca72e5e39/download
http://repositorio.ufes.br/bitstreams/fe0dd388-78a9-45af-a0ff-825bde547a4f/download
http://repositorio.ufes.br/bitstreams/fe4f15ae-436b-4808-a10a-536154f9c949/download
http://repositorio.ufes.br/bitstreams/ba806369-47cd-4989-a27f-c059385b161b/download
http://repositorio.ufes.br/bitstreams/33f35a13-1c76-48ae-b70b-99dfcb2168f0/download
bitstream.checksum.fl_str_mv 91d4c514416e14264549113d0ff5dea1
4afdbb8c545fd630ea7db775da747b2f
b292a83e42bd8ad62533bba1395b83ff
9da0b6dfac957114c6a7714714b86306
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES)
repository.mail.fl_str_mv
_version_ 1813022517911093248